This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Phase 1 Data Presented On First Oral Combination 17β-Estradiol And Progesterone Capsule To Treat Menopausal Symptoms Being Developed For FDA Review

TherapeuticsMD, Inc. (NYSE MKT: TXMD) - Pharmacokinetic study being presented tomorrow evening in a poster session at The North American Menopause Society 2013 Annual Meeting in Dallas suggests that the first combination 17β-estradiol and progesterone capsule in clinical development may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination.

In a study of 66 healthy postmenopausal women, bioavailability of TX 12-001-HR, a capsule containing both 17β-estradiol and progesterone for oral use being developed by TherapeuticsMD, Inc., was found to be similar to that of the standard reference products for the human hormones estradiol (Estrace ®) and progesterone (Prometrium ®), when taken concurrently. Hormone therapy is widely used to alleviate the symptoms of menopause and to reduce the health risks resulting from hormone deficiencies associated with menopause.

“It has been notoriously difficult to combine these two body-identical hormones and obtain consistently good bioavailability. And, when compounding pharmacies create specialized blends of these hormones, there is a great deal of variability in what is produced,” according to James H. Pickar, M.D., Adjunct Associate Professor of Obstetrics and Gynecology, Columbia University College of Physicians & Surgeons in New York, who presented the study findings. In two FDA surveys of compounding pharmacies, the amount of hormone found in the compounded products was not the amount claimed in approximately 34% of compounded products sampled and in 29% of hormone samples, versus the <2% variability found for commercially manufactured products. 1,2

In this study, bioequivalence criteria were met for all analytes, except C max for total estrone. The extent of absorption of the estradiol and progesterone in the Test capsule was similar to that for Estrace and Prometrium, while the rate of estradiol absorption for the Test capsule appeared to be slightly faster than for the Estrace reference.

“The similarity in bioavailability of progesterone and estradiol in the test product to that of the two reference products suggests that the safety profile also should be similar,” Dr. Pickar said. Studies suggest that products more closely resembling the human hormones progesterone and estradiol may have a more favorable safety profile than synthetic hormones. 3,4 Dr. Pickar also noted that this investigational therapy offers the additional advantage of avoiding use of the known allergen, peanut oil, which is used in Prometrium and its generic equivalents.

The need to ensure adequate bioavailability is critical for progesterone, which protects the endometrium from estrogen stimulation. “When progesterone levels are inadequate, women taking estrogen are put at unnecessary risk for uterine cancer,” added Dr. Pickar.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs